James Lyons-Weiler, PhD
August 31, 2026
HHS says hospitals and clinics turned distressed minors into recurring customers, secured payment through questionable coding, and expanded under federal and professional protection.
On August 13, 2026, the Department of Health and Human Services released Wolves in White Coats: How Doctors and Hospitals Pushed and Profited from the Fraud of ‘Gender Medicine.’ The 64-page commissioned report draws on insurance claims, CMS coding guidance, Justice Department investigations, hospital materials, whistleblower testimony, scientific literature, and interviews with patients and parents. Its conclusion is stated in the title: HHS says pediatric gender medicine became an industry that harmed children and rewarded the institutions delivering it. [1],[2]
The release was paired with federal referrals. Vice President JD Vance, acting as chairman of the White House Task Force to Eliminate Fraud, referred providers named in the report to the Department of Justice. Secretary Robert F. Kennedy Jr. sent the same claims cohorts to the HHS Office of Inspector General. Kennedy’s August 12 letter identifies providers whose claims exhibit ‘potentially anomalous billing patterns’ and asks OIG to investigate possible violations of federal law. [2],[3]
HHS describes a national system driven by three forces. Hospitals found a long-duration revenue model. Advocates and providers used diagnostic codes that could secure insurance payment when a gender-related diagnosis might fail. Federal officials and professional societies then supplied the legal, financial, and institutional protection that allowed the model to spread. The report’s five chapters build that case in sequence. [1]
The report’s central charge
HHS says hospitals enabled a rapid medical shift despite scant evidence for long-term safety and efficacy. The report uses the term ‘sex-rejecting procedures’ for puberty blockers, cross-sex hormones, mastectomy, genital reconstruction, and related operations. It argues that these interventions placed physically healthy minors on a path of repeated endocrine visits, laboratory monitoring, prescriptions, mental-health encounters, surgeries, revisions, and adult follow-up. [1]
The report was commissioned by HHS and written by contributors from the Center for Christian Virtue, Independent Women’s Forum, the Ethics and Public Policy Center, and clinical practice. They include Aaron Baer, Victoria Coley, Neeraja Deshpande, Eithan Haim, Jordan Jantz, Aaron Kheriaty, May Mailman, Andrea Mew, Rachel Morrison, and Quentin Van Meter. The report describes itself as noncomprehensive and points readers to a separate HHS evidence review for its full clinical assessment of pediatric gender medicine. [1],[5]
Its thesis is broader than insurance fraud. HHS says financial incentives attracted hospitals, gender ideology shaped clinicians and medical organizations, Biden-era policy pressured providers and payers to expand access, and weak oversight left families with few brakes on the process. The report presents the billing data as the most measurable part of a much larger institutional failure. [1]
A lifelong revenue stream
HHS traces the expansion from a handful of specialized clinics in the early 2010s to programs at more than 225 hospitals and health systems by the early 2020s. The report starts with the economics of pediatrics: lower physician compensation, thinner departmental margins, and less institutional influence than high-revenue adult specialties. Gender clinics, HHS says, changed that calculation by bringing endocrinology, adolescent medicine, plastic surgery, urology, and gynecology into a continuing chain of reimbursable care. [1]
The report calls this the ‘captive patient’ model. Endocrine Society and WPATH guidance called for clinical assessments every three to six months, periodic laboratory testing, bone-density scans, and continuing multidisciplinary follow-up. HHS interprets that schedule as a predictable stream of office visits, prescriptions, facility fees, monitoring, and later procedures extending into adulthood. [1]
The cost estimates cited by HHS are concrete. Annual payer spending averages about $545 for androgens, $735 for estrogens, and $16,385 for GnRH agonists. The report cites mean health-plan payments of $12,680 for mastectomy with chest masculinization, $17,426 for mammoplasty, $53,645 for vaginoplasty, and $133,911 for phalloplasty. It places lifetime spending at $25,000 to $75,000 without surgery and says combined operations can push the surgical total toward $170,000. Fertility preservation, voice therapy, hair removal, complication care, and later restorative treatment add more. [1]
At the institutional level, the report cites the Stop the Harm database for $119,791,202 in submitted charges since 2019, 5,747 minors recorded as having undergone surgeries, and 8,579 minors recorded as receiving hormones or puberty blockers. The same database placed Mount Sinai at more than $8.2 million and Boston Children’s Hospital at more than $6.5 million in billed charges from 2019 through 2023. HHS presents these figures as evidence that pediatric gender programs became meaningful revenue lines inside large health systems. [1]
How HHS says providers secured payment
The report’s second chapter centers on ICD diagnosis codes. CMS requires claims to describe the documented condition at the highest available specificity. HHS argues that some providers substituted physical-disease codes for gender-related diagnoses so that insurers, Medicaid, or Medicare would pay for puberty blockers and hormones. The report focuses on E34.9, endocrine disorder unspecified, and E30.1, central precocious puberty. [1],[4]
HHS cites earlier public evidence that E34.9 had become a proxy code. A 2016 CMS-linked study described the predecessor endocrine code as a way to avoid the stigma of a gender-identity diagnosis. A 2023 University of Iowa analysis used E34.9 to help identify gender-expansive patients because the code sometimes appeared in place of a gender-dysphoria code. The report interprets these practices as evidence that code substitution was known within the field. [1]
HHS then tested the pattern in nationwide all-payer claims from 2015 through 2025. Its first cohort identified puberty-blocker claims for patients ages 9 through 17 carrying an E34-family diagnosis while excluding claims containing an F64 gender diagnosis or E30.1 precocious-puberty diagnosis. HHS reports nearly $50 million in submitted charges across that cohort, including more than $40 million tied specifically to E34.9. The HHS press release summarizes the figure as approximately $50 million associated with E34.9; the report’s detailed analysis assigns more than $40 million to that specific code. [1],[2]
The second cohort identified nearly $11 million in puberty-blocker claims for patients ages 13 through 17 carrying E30.1. HHS notes that central precocious puberty ordinarily begins before age 8 in girls or age 9 in boys and that blocker treatment usually ends around ages 10 or 11. The report therefore treats claims carrying that diagnosis in teenagers as evidence of potentially false coding. [1]
HHS states its data limits in the appendix. Patient ages were estimated from birth year using July 1 as a default birthday. Dollar totals are submitted charges, and some claims carry null amounts. Organizations may appear under more than one spelling, and inclusion in the roster means only that an organization billed at least one qualifying claim. The report calls the results ‘directional signals rather than findings’ and sends investigators to the underlying records for verification. [1]
HHS says the coding practice was openly promoted
The report moves from claims patterns to statements by people and organizations in the field. It cites a 2021 WPATH training presentation that listed E34, E34.9, and hypogonadism codes in materials on insurance coverage and adolescent care. It cites QueerDoc’s public explanation that some providers use E34.9 for laboratory work, prescriptions, and visits. It also reproduces Planned Parenthood of Southeastern Pennsylvania’s statement that the organization typically used E34.9 and used a gender-identity code when necessary. [1]
HHS treats these statements as evidence of a billing workaround operating in plain sight. The report also recounts whistleblower allegations at Texas Children’s Hospital, state lawsuits alleging use of endocrine-disorder, precocious-puberty, and contraception codes, and federal inquiries seeking communications about alternative diagnoses. It connects those allegations to a May 2026 resolution under which Texas Children’s Hospital agreed to pay $10 million and create a clinic for detransitioners, and to a June 2026 Cleveland Clinic resolution that included $2 million for restorative care. [1]
The report recommends periodic Medicaid reviews of these codes, comparable controls inside managed-care organizations, and referral of suspicious claims to Medicaid Fraud Control Units, state attorneys general, U.S. attorneys, and other law-enforcement bodies. It also points to False Claims Act litigation by private relators as another route for recovering improper payments. [1]
The Biden administration supplied federal pressure
Chapter 3 argues that the Biden administration converted affirmation into federal policy. HHS begins with President Biden’s January 2021 executive order on gender-identity discrimination. It then traces the policy through the HHS Office for Civil Rights, which interpreted Section 1557 of the Affordable Care Act to reach refusals of treatment or insurance coverage. Federal courts later vacated the gender-identity portions of the 2022 guidance and the corresponding provisions of the 2024 rule. [1]
The report cites CMS approval of Colorado’s essential-health-benefits benchmark, which required coverage of a broad range of interventions, and the CMS administrator’s invitation for other states to follow. It cites a March 2022 Office of Population Affairs document endorsing blockers, hormones, chest surgery, and genital surgery for young people, even though the Food and Drug Administration had approved neither blockers nor cross-sex hormones for gender-related use. It also recounts federal employee coverage directives, litigation positions, grants, and agency programs that HHS says normalized and financed the model. [1]
The report’s point is institutional. Hospitals encountered a federal government that treated access as a protected policy objective through civil-rights enforcement, coverage directives, official clinical messaging, federal spending, and legal intervention. HHS says those policies rewarded expansion and discouraged resistance inside medical systems. [1]
Medical societies manufactured consensus
Chapter 4 says professional-society bias carried the same ideology into hospital practice. HHS describes extensive overlap between WPATH and the authors of Endocrine Society guidance. It points to recommendations allowing hormones before age 16 in some cases while acknowledging minimal published research below roughly age 14. The report also faults the guideline process for failing to disclose whether authors or affiliated clinicians stood to benefit from wider use of the interventions. [1]
HHS makes a similar argument about the American Psychological Association and the American Academy of Pediatrics. It reports that at least seven members of the APA’s eight-person task force were WPATH members or affiliates. It says the AAP’s 2018 policy developed from work involving the Human Rights Campaign, was approved by a 13-member board without a vote of the organization’s 67,000 members, and was reaffirmed in 2023 before the AAP completed its own systematic evidence review. [1]
The report says these organizations created the appearance of settled medical consensus, which hospitals then converted into protocols, referrals, consent materials, and standards of care. HHS presents professional endorsement as a mechanism of institutional capture: a small group writes guidance, large associations adopt it, and hospitals treat the resulting policy as authoritative. [1]
The people HHS put on the record
The final substantive chapter presents accounts from Sydney Aviles, Lily Burns, Rose Marie, Clementine Breen, Layla Jane, Christy Davidson, Soren Aldaco, and Luke Healy. HHS uses their experiences to show how vulnerable young people entered treatment, how clinicians handled doubt and co-occurring distress, what physical consequences followed, and how little organized care existed for patients who wanted to reverse course. [1]
Sydney Aviles describes beginning testosterone, paying $10,000 for a double mastectomy at 18, developing thyroid dysfunction and an elevated red-blood-cell count, and stopping testosterone when vasovagal syncope made therapeutic blood draws untenable. Soren Aldaco describes testosterone, mastectomy, a severe postoperative hematoma, continued medicalization despite worsening symptoms, and no structured detransition plan when she stopped. Luke Healy describes online exposure beginning at 10, estrogen treatment after turning 18, a surgical consultation quoting about $200,000 for facial feminization, and lasting gynecomastia after detransition. [1]
These accounts supply the human argument behind the claims analysis. HHS portrays an organized pathway into treatment and an improvised pathway out. Referrals, approvals, prescriptions, surgery, and billing were available; reassessment, long-term outcome tracking, and restorative care were scarce. [1]
What HHS wants done
The report calls for federal and state review of coding and billing, stronger program-integrity controls, referral of suspicious claims, protection for whistleblowers, and continued scrutiny of the clinical practices and policies surrounding pediatric gender medicine. The August 13 referrals put that recommendation into motion. Vance sent the provider list to DOJ. Kennedy sent an objectively defined claims cohort to OIG. [1],[2],[3]
For the clinical evidence, Wolves in White Coats points to HHS’s separate Treatment for Pediatric Gender Dysphoria review. The policy report uses that evidence judgment as its premise: hospitals expanded irreversible and long-duration interventions while safety and efficacy remained inadequately established. Its own contribution is the institutional account of how money, coding, federal policy, professional authority, and ideology worked together. [1],[5]
HHS closes by saying the potential fraud is only the ‘tip of the iceberg.’ That is the case the department has placed before DOJ, OIG, state Medicaid programs, insurers, hospitals, and the public. The report names the revenue model, the diagnostic codes, the institutions, the policy machinery, and the patients who say they were harmed. The investigation now begins where the report ends: inside the claims and medical records. [1],[2],[3]
Sources
2. HHS release announcing Wolves in White Coats and the federal referrals
3. Secretary Kennedy’s referral letter to the HHS Office of Inspector General
4. CMS, FY 2025 ICD-10-CM Official Guidelines for Coding and Reporting
5. HHS, Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices
This describes medical malpractice to the extreme. All of these doctors and hospitals need removal from licenses, banned from medical practice for life. Those school systems that refuse to tell parents of their child's gender issues need to be banned from public funding.
I trained at Hutzel Detroit in 80’s , never allowed to participate as an ob gyn resident…. Plastics and gyn onc participated but very rare cases with their own area for recovery… years of counseling… most pts were 50 year olds . The indoctrination nowadays is disgraceful and disgusting.